Why menopause may cause low libido
Declining estrogen reduces vaginal blood flow, lubrication, and clitoral sensitivity, while declining ovarian testosterone reduces baseline sexual desire and arousal. Sleep disruption and mood changes compound the picture. Genitourinary syndrome of menopause makes intercourse uncomfortable, which further suppresses spontaneous desire.
How common is this?
Roughly 40 percent of postmenopausal women report distressing low desire, and around half report vaginal dryness or pain with intercourse. The combination is often called hypoactive sexual desire disorder plus genitourinary syndrome and responds well to combination treatment.
Estimated monthly US search volume: 6,600/mo.
Treatment options
Vaginal estrogen (cream, tablet, or ring) is first-line for the genitourinary component and is safe long-term at low doses. Systemic HRT helps overall desire when vasomotor symptoms also drive fatigue. Off-label transdermal testosterone at postmenopausal-female doses (roughly 300 mcg daily) improves desire in randomized trials.
Providers we've reviewed that treat this concern (navigational only — editorial ranking, not medical endorsement):
- Defy Medical — testosterone-inclusive protocols for libido + energy complaints
- Joi Women's Wellness — clinician-led HRT platform with prescriber consult included in the monthly fee
- Esme Wellness — concierge-style menopause care with unlimited messaging
Browse the full menopause provider catalogue or read our editorial methodology.
Frequently asked questions
- Is testosterone safe for women?
- At postmenopausal-female doses (roughly one-tenth of male replacement) transdermal testosterone has good short-term safety data. Long-term outcomes beyond two years are less well studied.
- Does vaginal estrogen affect the whole body?
- Very little. Serum estradiol remains at postmenopausal levels with standard low-dose vaginal preparations, so systemic risks are minimal.
- What about flibanserin or bremelanotide?
- Both are FDA-approved for premenopausal HSDD. Off-label use in postmenopausal women is possible but data are limited.
- Will HRT alone fix libido?
- Estrogen improves the vaginal component but usually needs testosterone to move desire. Combination treatment gives the best outcomes.
Related reading
Sources
- PubMedDavis SR, et al. Global Consensus Position Statement on Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666.
- NAMSThe North American Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
- ACOGAmerican College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 141: Management of Menopausal Symptoms. Obstet Gynecol. 2014;123(1):202-216.
- NIHNational Institute on Aging. What Is Menopause? U.S. Department of Health & Human Services (updated 2024).